Xalud Therapeutics

Cell Source, Inc. is a pioneering biotechnology company based in New York, focused on developing next-generation immunotherapy solutions that enable rejection-free organ transplantation and safe stem cell treatments. Utilizing their innovative Veto Cell protocols, the company addresses significant challenges in allogeneic transplantation, including donor matching, graft versus host disease, and life-threatening infections. Under the leadership of Professor Yair Reisner, a prominent figure in immunology, Cell Source is advancing therapeutic approaches for various conditions such as leukemia, organ transplants, and non-malignant diseases like type-1 diabetes and multiple sclerosis. With a commitment to improving patient outcomes and quality of life, the company has achieved notable milestones, including the First In Human status for its Veto Cells in September 2019, and is currently conducting a Phase I/II clinical trial. Generated from the website

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. Through the years the company has maintained a strong focus on innovation. Its BioSpherix division is currently running a Phase 3 clinical trial to study the use of the company's Naturlose product as a treatment for Type 2 diabetes. Spherix Health Sciences Consulting division provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of: conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. It has corporate headquarters in Beltsville, Md., and additional offices in Maryland, Tennessee and South Dakota.

Aptorum Group Limited is a clinical stage biopharmaceutical company based in New York, NY. They are dedicated to discovering, developing, and commercializing therapeutic assets to treat diseases with unmet medical needs, particularly in oncology and infectious diseases. Their pipeline includes drug discovery platforms and a novel molecular-based rapid pathogen identification and detection diagnostics technology. Aptorum Group is focused on facilitating the development of medical innovations that can significantly improve clinical and surgical experiences and meet current unmet medical needs. With a deep portfolio and strong life science development capabilities, they are driven by the enthralling market potential and growth prospects in the field of healthcare. Their mission is to tackle unmet medical needs and make a positive impact on patients' lives.Generated from the website